ouabain has been researched along with Hypertrophy, Left Ventricular in 9 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (11.11) | 18.2507 |
| 2000's | 5 (55.56) | 29.6817 |
| 2010's | 3 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bianchi, G; Casamassima, N; Fagard, RH; Jin, Y; Kuznetsova, T; Manunta, P; Messaggio, E; Richart, T; Staessen, JA; Thijs, L | 1 |
| Betlehem, J; Cseh, J; Cziráki, A; Fehér, E; Gaszner, B; Kõszegi, T; Lányi, É; Markó, L; Nagy, G; Sulyok, E; Wittmann, I | 1 |
| Gan, XT; Huang, C; Hunter, JC; Javadov, S; Karmazyn, M; Rajapurohitam, V; Xue, J | 1 |
| Cui, XP; Gao, HQ; Ji, X; Liu, XJ; Qiu, J; Wang, Y; You, BA; Zhao, SH | 1 |
| Bianchi, G; De Tommasi, E; Forleo, C; Guida, P; Hamlyn, JM; Iacoviello, M; Lucarelli, K; Manunta, P; Messaggio, E; Pitzalis, MV; Rizzon, P; Romito, R | 1 |
| Babeanu, S; Bianchi, G; Brand, E; Brand-Herrmann, SM; Casiglia, E; Cwynar, M; Filipovský, J; Grodzicki, T; Kawecka-Jaszcz, K; Kuznetsova, T; Nikitin, Y; Peleska, J; Staessen, JA; Stolarz, K; Struijker-Boudier, H; Thijs, L; Tikhonoff, V; Wojciechowska, W | 1 |
| Bianchi, G; Hamlyn, JM; Malatino, LS; Mallamaci, F; Manunta, P; Melandri, M; Spotti, D; Stella, P; Tripepi, G; Zoccali, C | 1 |
| Bianchi, G; Ciurlino, D; Cusi, D; Ferrandi, M; Hamlyn, JM; Manunta, P; Rivera, R; Stella, P | 1 |
| Dalton, GR; Evans, SJ; Levi, AJ | 1 |
2 review(s) available for ouabain and Hypertrophy, Left Ventricular
| Article | Year |
|---|---|
Sodium excretion as a modulator of genetic associations with cardiovascular phenotypes in the European Project on Genes in Hypertension.
Topics: Blood Pressure; Calmodulin-Binding Proteins; Cytochrome P-450 CYP11B2; Heart Rate; Humans; Hypertension; Hypertrophy, Left Ventricular; Ouabain; Peptidyl-Dipeptidase A; Phenotype; Polymorphism, Genetic; Receptor, Angiotensin, Type 1; Sodium | 2006 |
Experimental studies on myocardial stretch and ventricular arrhythmia in hypertrophied and non-hypertrophied hearts.
Topics: Animals; Arrhythmias, Cardiac; Calcium; Calcium Channel Blockers; Cardiotonic Agents; Death, Sudden, Cardiac; Dogs; Electrocardiography; Gadolinium; Heart; Heart Ventricles; Humans; Hypertension; Hypertrophy, Left Ventricular; Isoproterenol; Meta-Analysis as Topic; Models, Cardiovascular; Myocardial Contraction; Myocardium; Nifedipine; Ouabain; Quinolines; Randomized Controlled Trials as Topic; Rats; Rats, Inbred SHR; Rats, Wistar; Ryanodine; Thiadiazines; Vasodilator Agents | 2000 |
1 trial(s) available for ouabain and Hypertrophy, Left Ventricular
| Article | Year |
|---|---|
Selective association of endogenous ouabain with subclinical organ damage in treated hypertensive patients.
Topics: Aged; Antihypertensive Agents; Biomarkers; Blood Pressure Monitoring, Ambulatory; Carotid Artery, Common; Catecholamines; Chronic Disease; Circadian Rhythm; Diabetes Mellitus, Type 2; Echocardiography; Female; Humans; Hypertension; Hypertrophy, Left Ventricular; Kidney Diseases; Male; Middle Aged; Natriuretic Peptide, Brain; Ouabain; Peptide Fragments; Risk Factors | 2011 |
6 other study(ies) available for ouabain and Hypertrophy, Left Ventricular
| Article | Year |
|---|---|
Left ventricular geometry and endogenous ouabain in a Flemish population.
Topics: Adult; Aged; Belgium; Female; Humans; Hypertrophy, Left Ventricular; Male; Middle Aged; Ouabain; Phenotype; Ventricular Function, Left; Ventricular Remodeling | 2009 |
Ouabain increases iNOS-dependent nitric oxide generation which contributes to the hypertrophic effect of the glycoside: possible role of peroxynitrite formation.
Topics: Animals; Cardiotonic Agents; Cell Shape; Cells, Cultured; Dose-Response Relationship, Drug; Enzyme Induction; Enzyme Inhibitors; Extracellular Signal-Regulated MAP Kinases; Hypertrophy, Left Ventricular; L-Lactate Dehydrogenase; Male; Myocytes, Cardiac; Nitric Oxide; Nitric Oxide Synthase Type II; Ouabain; p38 Mitogen-Activated Protein Kinases; Peroxynitrous Acid; Phosphorylation; Rats; Rats, Sprague-Dawley; RNA, Messenger; Signal Transduction; Superoxides; Time Factors; Tyrosine; Up-Regulation | 2012 |
Effect of ouabain on myocardial ultrastructure and cytoskeleton during the development of ventricular hypertrophy.
Topics: Animals; Blood Pressure; Cytoskeleton; Desmin; Disease Models, Animal; Disease Progression; Gene Expression Regulation; Hypertrophy, Left Ventricular; Male; Microscopy, Electron, Transmission; Myocardium; Ouabain; Profilins; Rats; Rats, Sprague-Dawley; Real-Time Polymerase Chain Reaction; RNA, Messenger | 2013 |
High circulating levels of endogenous ouabain in the offspring of hypertensive and normotensive individuals.
Topics: Adult; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Echocardiography, Doppler; Family Health; Female; Humans; Hypertension; Hypertrophy, Left Ventricular; Linear Models; Male; Ouabain | 2005 |
Endogenous ouabain and cardiomyopathy in dialysis patients.
Topics: Adult; Aged; Biomarkers; Blood Pressure; Cohort Studies; Female; Humans; Hypertrophy, Left Ventricular; Kidney Failure, Chronic; Male; Middle Aged; Ouabain; Predictive Value of Tests; Renal Dialysis; Ultrasonography; Ventricular Remodeling | 2008 |
Left ventricular mass, stroke volume, and ouabain-like factor in essential hypertension.
Topics: Adult; Female; Humans; Hypertension; Hypertrophy, Left Ventricular; Male; Middle Aged; Ouabain; Regression Analysis; Stroke Volume; Ventricular Function | 1999 |